UNIV(301166)

Search documents
优宁维(301166) - 关于2025年第一季度计提资产减值准备的公告
2025-04-28 10:23
证券代码:301166 证券简称:优宁维 公告编号:2025-041 上海优宁维生物科技股份有限公司 关于 2025 年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")根据《深圳证券交易 所创业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号 —业务办理第一章信息披露:第二节定期报告披露相关事宜》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及公司相关会计政 策的规定,基于谨慎性原则,为了真实准确地反映公司的资产和财务状况,对合 并报表范围内截至 2025 年 3 月 31 日的各类应收款项、固定资产等进行了全面 清查。对各项资产减值的可能性进行了充分的评估和分析,判断存在可能发生减 值的迹象,确定了需计提的减值准备。现将有关情况公告如下: 一、本次计提资产减值准备情况概述 本次计提资产减值准备计入的报告期间为 2025 年 1 月 1 日至 2025 年 3 月 31 日。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易 ...
优宁维(301166) - 2025 Q1 - 季度财报
2025-04-28 10:15
Revenue and Profit - The company's revenue for Q1 2025 was ¥216,368,460, a decrease of 20.34% compared to ¥271,631,039.66 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥6,208,677.82, representing a decline of 219.34% from a profit of ¥5,202,522.95 in the previous year[5] - Total operating revenue decreased to ¥216,368,460.00 from ¥271,631,039.66, representing a decline of approximately 20.4% year-over-year[19] - Net profit for the period was a loss of ¥6,208,677.82, compared to a profit of ¥5,202,522.95 in the previous period, indicating a significant decline[20] - The company reported a gross profit margin of approximately -6.5% for the current period, compared to a positive margin in the previous period[19] - Basic and diluted earnings per share were both -¥0.07, down from ¥0.06 in the previous period, reflecting the company's financial challenges[20] Cash Flow and Investments - The net cash flow from operating activities improved to -¥23,026,807.37, a 60.97% increase compared to -¥58,999,143.47 in the same period last year[5] - Operating cash flow for the current period is -23,026,807.37, an improvement from -58,999,143.47 in the previous period, indicating a reduction in cash outflow[21] - Total cash inflow from investment activities decreased to 478,295,415.16 from 862,538,137.50, reflecting a significant decline in investment recovery[21] - Net cash flow from investment activities is -399,837,948.09, worsening from -57,230,490.63 in the previous period, highlighting increased cash outflow for investments[21] - Cash and cash equivalents at the end of the period stand at 401,022,528.97, up from 295,240,832.24 in the previous period[22] - The company reported a total cash outflow from financing activities of 7,930,876.13, compared to 3,069,512.87 in the previous period, indicating increased cash payments related to financing[22] - The net increase in cash and cash equivalents for the current period is -430,809,072.97, a significant decline from -119,286,312.09 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,247,681,984.83, down 2.67% from ¥2,309,420,442.59 at the end of the previous year[5] - The company's total assets decreased to ¥2,247,681,984.83 from ¥2,309,420,442.59, a reduction of approximately 2.7%[18] - Total liabilities decreased to ¥192,699,789.46 from ¥241,515,885.28, a decline of about 20.2% year-over-year[18] - The company’s total equity decreased to ¥2,054,982,195.37 from ¥2,067,904,557.31, a decline of about 0.6% year-over-year[18] Shareholder Information - The company had a total of 10,851 common shareholders at the end of the reporting period[10] - The top two shareholders held 43.45% of the company's shares, with the largest shareholder owning 33.09%[11] - The company repurchased a total of 927,600 shares, accounting for 1.07% of the total share capital, with a total expenditure of RMB 25,987,076[14] - The maximum repurchase price was RMB 31 per share, while the minimum was RMB 24.98 per share[14] - The company plans to use between RMB 15 million and RMB 30 million of its own funds for further share repurchases, with a maximum price of RMB 44 per share[14] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[13] - The company has not disclosed any information regarding preferred shareholders or restricted shares[14] Financial Performance Metrics - The weighted average return on net assets was -0.45%, a decrease of 0.47% from 0.02% in the previous year[5] - Research and development expenses were ¥14,595,809.76, slightly down from ¥14,643,002.03, indicating stable investment in innovation[20] - Deferred income tax assets increased to ¥84,119,128.98 from ¥76,299,993.81, suggesting potential future tax benefits[18] Other Information - The company experienced a 90.39% increase in taxes and surcharges, amounting to ¥705,653.94, primarily due to an increase in property tax[9] - Financial expenses decreased by 75.62% to -¥848,293.79, attributed to currency exchange rate fluctuations[9] - The company has not yet adopted the new accounting standards as of the first quarter report[23] - The first quarter report has not been audited, which may affect the reliability of the financial data presented[23]
优宁维(301166) - 301166优宁维投资者关系管理信息20250425
2025-04-25 10:02
投资者关系活动记录表 编号:2025-003 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | 媒体采访 业绩说明会 | | 类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 (电话会议) | | | 东证资管 徐宏 陈峻松 | | 参与单位名称及 | 易方达基金 | | | 中邮基金 杨朋、李谭 | | 人员姓名 | 信达澳亚基金 李东升 | | | 国盛证券 杨芳 | | 时间 | 年 月 日上午 下午 2025 4 25 9:30-11:30 15:00~17:00 | | 地点 | 公司会议室 | | 上市公司接待 | 祁艳芳 董事、副总经理、董事会秘书 | | 人员姓名 | 证券事务代表 夏庆立 | | | 一、公司基本情况介绍 | | | 公司向投资者简要介绍了公司基本情况及 2024 年度经营情况。 | | | 二、问答环节 | | | 1、关税政策影响 | | | 答:加征关税对公司出口影响较小(出口比重很低)。加征关税对公 | | | 司进口原产自美国的产品进口有一定影响,与此同时,对于公司的自 | | | 主 ...
破发股优宁维2股东拟减持 上市见顶超募13亿净利降3年
Zhong Guo Jing Ji Wang· 2025-04-23 05:35
其中以集中竞价交易方式减持在任意连续90日内,减持股份的总数不超过公司扣除回购专户股份后总股 本的1%;以大宗交易方式减持在任意连续90日内,减持股份的总数不得超过公司扣除回购专户股份后 总股本的2%。 上市次日,优宁维盘中创下股价最高点136元,此后股价震荡下跌。目前该股处于破发状态。 优宁维首次公开发行股票募集资金总额为18.65亿元,扣除发行费用后,募集资金净额为15.96亿元。优 宁维最终募集资金净额比原计划多13.12亿元。优宁维于2021年12月23日披露的招股说明书显示,公司 拟募集资金2.83亿元,计划分别用于线上营销网络与信息化建设项目、线下营销及服务网络升级项目、 研发中心建设项目、补充流动资金项目。 中国经济网北京4月23日讯优宁维(301166)(301166.SZ)昨日晚间披露公告称,股东上海创业接力泰礼 创业投资中心(有限合伙)(以下简称"泰礼投资")及其一致行动人上海泰礼创业投资管理有限公司-上海含 泰创业投资合伙企业(有限合伙)(以下简称"含泰投资")计划自减持计划公告披露之日起15个交易日后的3 个月内通过集中竞价或大宗交易的方式合计减持不超过2,572,172股,减持比例不 ...
上海优宁维生物科技股份有限公司
Shang Hai Zheng Quan Bao· 2025-04-21 20:57
登录新浪财经APP 搜索【信披】查看更多考评等级 二、本次会计政策变更对公司的影响 本次会计政策变更是公司根据财政部修订的最新会计准则进行的相应变更,符合相关法律法规的规定和 公司实际情况,不会对公司财务状况、经营成果和现金流量产生重大影响,不存在损害公司及全体股东 利益的情形。 三、董事会对本次会计政策变更合理性的说明 经审核,董事会认为:本次会计政策变更是公司根据财政部发布的《企业会计准则解释第18号》(财会 〔2024〕24号)的要求进行的相应变更,符合相关法律法规的规定和公司实际情况,不存在损害公司和 全体股东利益的情形。因此,董事会同意本次会计政策的变更。 四、监事会关于会计政策变更的意见 经审核,监事会认为:本次会计政策变更是根据财政部相关文件要求进行的合理变更,符合《企业会计 准则》及相关规定,符合公司实际情况,能够客观、公允地反映公司的财务状况和经营成果,本次会计 政策变更的决策程序符合有关法律、法规和《公司章程》的规定,不存在损害公司和中小股东利益的情 形。 五、备查文件 1、公司第四届董事会第五次会议决议; 2、公司第四届监事会第五次会议决议。 特此公告。 上海优宁维生物科技股份有限公司董 ...
上海优宁维生物科技股份有限公司 2024年度内部控制自我评价报告
Zheng Quan Ri Bao· 2025-04-21 18:25
Core Viewpoint - The company, Shanghai Univey Biotech Co., Ltd., has conducted a self-evaluation of its internal control effectiveness as of December 31, 2024, and found no significant defects in both financial and non-financial reporting internal controls [3][34]. Internal Control Evaluation Conclusion - The board of directors concluded that the company has maintained effective internal controls over financial reporting in all significant aspects [3]. - No significant defects were identified in non-financial reporting internal controls as of the evaluation report date [3]. Internal Control Evaluation Work Situation Evaluation Scope - The evaluation scope was determined based on a risk-oriented principle, covering the company and its important subsidiaries, focusing on five main elements of internal control: internal environment, risk assessment, control activities, information and communication, and internal supervision [4]. Internal Environment - The company has established a governance structure in compliance with relevant laws and regulations, ensuring effective division of responsibilities and checks and balances [5][6]. - Internal audit functions are managed by the corporate management department, which oversees both internal and external audits [8]. Risk Assessment - The company has identified various internal risk factors, including management integrity, employee competence, and operational safety, and has established a risk management framework to address these risks [10][11]. Control Activities - The company has implemented control policies and procedures, including authorization management, segregation of incompatible duties, accounting system controls, asset protection controls, and independent auditing controls [13][14]. Information and Communication Control - A robust information and communication system has been established, ensuring effective information flow across departments and timely financial reporting [15]. Internal Control Defects Recognition and Rectification - The company has not identified any significant or important defects in internal controls during the reporting period [34]. Company Overview Main Business - The company provides life science reagents and related instruments, consumables, and comprehensive technical services, focusing on antibody-based products [38]. - It has integrated over 60 well-known brands and offers more than 9.7 million SKUs, covering various research areas in life sciences [38][41]. Operating Model - The company employs a dual procurement model, including stock procurement and sales-driven procurement, to meet the diverse needs of its clients [42]. - Sales are conducted through a nationwide network of subsidiaries and offices, complemented by an online platform [43][44]. Production Model - The company primarily acts as an agent for third-party brand products while also engaging in self-production through its subsidiaries [48][49]. Research and Development - The company focuses on innovative research and development based on customer needs, with dedicated teams for product and technology development [51][53].
优宁维(301166) - 关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
2025-04-21 10:20
证券代码:301166 证券简称:优宁维 公告编号:2025-036 上海优宁维生物科技股份有限公司 关于作废 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 20 日 召开第四届董事会第五次会议和第四届监事会第五次会议,审议通过了《关于作 废 2022 年限制性股票激励计划部分已授予尚未归属的限制性股票的议案》,现将 有关事项说明如下: 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 1、2022 年 2 月 20 日,公司召开第三届董事会第三次会议,会议审议通过 了《关于公司<2022 年限制性股票激励计划(草案)>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会 授权董事会办理限制性股票激励计划相关事宜的议案》。公司独立董事就本次激 励计划相关议案发表了独立意见。 同日,公司召开第三届监事会第二次会议,审议通过了《关于公司<2022 年 限制 ...
优宁维(301166) - 关于上海优宁维生物科技股份有限公司2022年限制性股票激励计划部分已授予尚未归属的限制性股票作废事项的法律意见书
2025-04-21 10:19
上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票作废事项的 法律意见书 地址:上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话:021-20511000 传真:021-20511999 邮编:200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票作废事项的 法律意见书 致:上海优宁维生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受上海优宁维生物科技股 份有限公司(下称"优宁维"或"公司")的委托,根据《中华人民共和国公司 法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券 法》")、《上市公司股权激励管理办法》(以下简称"《管理办法》")、《深圳 证券交易所创业板股票上市规则》(以下简称"《创业板上市规则》")以及《上 海优宁维生物科技股份有限公司章程》(以下简称"《公司章程》")等有关规 定,本所现就优宁维 2022 年限制性股票激励计划(以下简称"本 ...
优宁维(301166) - 2024年年度审计报告
2025-04-21 10:19
上海优宁维生物科技股份有限公司 审计报告 立信中联审字[2025]D—0596 号 立信中联会计师事务所(特殊普通合伙) LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 目 录 | 一、 | 审计报告 | 1—5 | | --- | --- | --- | | 二、 | 财务报表 | | | 1、 | 合并资产负债表、母公司资产负债表 | 1—4 | | 2、 | 合并利润表、母公司利润表 | 5—6 | | 3、 | 合并现金流量表、母公司现金流量表 | 7—8 | | 4、 | 合并所有者权益变动表、母公司所有者权益变动表 | 9—12 | | 5、 | 财务报表附注 | 1—104 | 立信中联会计师事务所(特殊普通合伙) LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 审计报告 三、关键审计事项 关键审计事项是我们根据职业判断,认为对本期财务报表审计最为重要的事 项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景,我们不 对这些事项单独发表意见。 审计报告 第 1 页 立信中联审字[20 ...
优宁维(301166) - 民生证券股份有限公司关于上海优宁维生物科技股份有限公司2024年度持续督导跟踪报告
2025-04-21 10:19
民生证券股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称:民生证券股份有限公司 | 被保荐公司简称:优宁维 | | --- | --- | | 保荐代表人姓名:孙银 | 联系电话:(021)60876732 | | 保荐代表人姓名:蒋红亚 | 联系电话:(021)60876732 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | (1)是否及时审阅公司信息披露文件 | 是 | | (2)未及时审阅公司信息披露文件的次数 | 0次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | (1)是否督导公司建立健全规章制度(包括但不限于防 止关联方占用公司资源的制度、募集资金管理制度、内 | 是 | | 控制度、内部审计制度、关联交易制度) | | | (2)公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | (1)查询公司募集资金专户次数 | 每月一次 | | (2)公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | (1)列席公司股东大会次数 | ...